Drug Profile


Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Transparency Life Sciences
  • Class Antihypertensives; Heart failure therapies; Small molecules
  • Mechanism of Action ACE inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Cardiovascular disorders
  • Preclinical Multiple sclerosis

Most Recent Events

  • 08 Sep 2014 Transparency Life Sciences receives SBIR grant from the National Center for Advancing Translational Sciences for lisinopril development in Multiple Sclerosis
  • 18 Dec 2012 Preclinical trials in Multiple sclerosis (adjunctive treatment) in USA (unspecified route)
  • 18 Dec 2012 The US FDA approves IND application for lisinopril as an adjunctive therapy in Multiple sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top